We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock
SRRA

Delisted

SRRA was delisted on the 30th of June, 2022.

Back to rankings

60 hedge funds and large institutions have $76.5M invested in Sierra Oncology, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

12% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 17

14% less funds holding

Funds holding: 70 → 60 (-10)

46% less capital invested

Capital invested by funds: $141M → $76.5M (-$64.9M)

67% less funds holding in top 10

Funds holding in top 10: 3 → 1 (-2)

67% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 15

Holders
60
Holders Change
-10
Holders Change %
-14.29%
% of All Funds
1.37%
Holding in Top 10
1
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-66.67%
% of All Funds
0.02%
New
5
Increased
15
Reduced
17
Closed
15
Calls
$34K
Puts
–
Net Calls
+$34K
Net Calls Change
+$64K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$4.5M
2
PM
Prosight Management
Texas
+$2.07M
3
Citadel Advisors
Citadel Advisors
Florida
+$1.24M
4
MP
Mangrove Partners
Connecticut
+$1.1M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.1M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$5.22M
2
GPP
Great Point Partners
Connecticut
-$4.06M
3
PA
Perceptive Advisors
New York
-$2.95M
4
DCM
Driehaus Capital Management
Illinois
-$2.37M
5
Millennium Management
Millennium Management
New York
-$1.88M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
26
Sectoral Asset Management
Quebec, Canada
$343K – – –
UBS Group
27
UBS Group
Switzerland
$331K -$64.8K -714 -13%
JP Morgan Chase
28
JP Morgan Chase
New York
$248K -$153K -1,683 -32%
KAM
29
Kazazian Asset Management
Florida
$201K – – –
CC
30
Caxton Corporation
New Jersey
$190K +$177K +1,954 +232%
BFM
31
Boothbay Fund Management
New York
$187K – – –
Connor, Clark & Lunn Investment Management (CC&L)
32
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$141K -$45.3K -500 -19%
FAM
33
Fred Alger Management
New York
$141K – – –
Two Sigma Investments
34
Two Sigma Investments
New York
$92K -$88.4K -975 -42%
Two Sigma Advisers
35
Two Sigma Advisers
New York
$70K +$1.81K +20 +2%
Goldman Sachs
36
Goldman Sachs
New York
$69K -$261K -2,879 -74%
WS
37
Wedbush Securities
California
$68K +$90.2K +995 New
ASN
38
Advisory Services Network
Georgia
$63K – – –
PNC Financial Services Group
39
PNC Financial Services Group
Pennsylvania
$61K – – –
RJT
40
Raymond James Trust
Florida
$61K – – –
Geode Capital Management
41
Geode Capital Management
Massachusetts
$60K – – –
Invesco
42
Invesco
Georgia
$57K -$635 -7 -0.8%
OAM
43
Oxford Asset Management
United Kingdom
$51K +$66.8K +737 New
ARTA
44
A.R.T. Advisors
New York
$46K +$61.4K +677 New
Wells Fargo
45
Wells Fargo
California
$45K -$3.63K -40 -6%
Comerica Bank
46
Comerica Bank
Texas
$42K – – –
PAM
47
Panagora Asset Management
Massachusetts
$40K -$1.81K -20 -3%
D.E. Shaw & Co
48
D.E. Shaw & Co
New York
$39K +$52K +573 New
COI
49
Connable Office Inc
Michigan
$32K – – –
BAS
50
Brown Advisory Securities
Maryland
$31K – – –
1
2
3

SRRA Hedge Fund Activity: Q3 2018 in Review

60 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q3 2018, worth a combined $76.5M — down 46% from $141M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of SRRA and 5 opened new positions — a net loss of 10 holders — while 17 trimmed existing stakes and 15 added.

The largest buyer was Broadfin Capital, adding an estimated $4.5M. The largest seller was Deerfield Management, exiting entirely with an estimated $5.22M sold.

  • 60 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q3 2018, down from 70 in Q2 2018.
  • Funds reported $76.5M of Sierra Oncology, Inc. Common Stock stock for Q3 2018, down 46% quarter-over-quarter.
  • 5 funds opened new Sierra Oncology, Inc. Common Stock positions in Q3 2018 and 15 closed out, a net change of -10 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q3 2018 was Broadfin Capital, an estimated $4.5M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q3 2018 was Deerfield Management, an estimated $5.22M sold.

Based on aggregated 13F filings for Q3 2018.